Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Patent
1995-01-26
1998-06-02
Campbell, Bruce R.
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
424 931, 424 932, 424 933, 424 937, 935 59, 935 62, A01N 4800, A01N 6300, A01N 6500
Patent
active
057595364
ABSTRACT:
A method for inhibiting T-lymphocyte-mediated immune responses, including those directed against autologous and/or heterologous tissues, e.g., by a recipient mammal of a transplanted tissue, said method comprising providing the recipient mammal with Fas ligand. The Fas ligand may be provided to the recipient mammal by a variety of means, including by pump implantation or by transplantation of transgenic tissue expressing Fas ligand. Also provided is a method for diagnostic use of Fas ligand expression in improving transplantation success.
REFERENCES:
patent: 5219740 (1993-06-01), Miller et al.
patent: 5283058 (1994-02-01), Faustman
S Nagata et al (1995) Science 267:1449-1456.
LB Owen-Schaub et al (1992) Cellular Immunology 140: 197-205.
R Jaenisch (1988) Science 240: 1468-1474.
MD Walker et al (1983) Nature 306: 557-561.
JD Watson et al (1987) Molecular Biology of the Gene, p. 313.
Naji et al., "The Influence of Histocompatibility and Transplant Site on Parathyroid Allograft Survival," J. Surgical Research (1976) 20:261-267.
Naji et al., Spontaneously Diabetes in Rats: Destruction of Islets Is Prevented by Immunological Tolerance, Science (1981) 213:1390-1392.
Selawry et al., "Intratesticular Islet Allografts in the Spontaneous Diabetic BB/W Rat," Diabetes (1985) 34:1019-1024.
Bellgrau and Selawry, "Cyclosporine-induced Tolerance to Intratesticular Islet Xenografts," Transplantation (1990) 50:654-657.
London et al., "A Simple Method for the Release of islets by Controlled Collagenase Digestion of the Human Pancreas," Transplantation (1990) 49:1109-1113.
Selawry et al., "Production of a Factor, or Factors, Suppressing IL-2 Production and T Cell Proliferation by Sertoli Cell-enriched Preparations," Transplantation (1991) 52:846-850.
Suda et al., "Molecular Cloning and Expression of the Fas Ligand, a Novel Member of the Tumor Necrosis Factor Family" Cell (1993) 75:1169-1178.
Selawry and Cameron, "Sertoli Cell-enriched Fractions in Successful Islet Cell Transplantation," Cell Transplantation (1993) 2:123-129.
Suda and Nagata, "Purification and Characterization of the Fas-ligand that Induces Apoptosis," J. Exp. Med. (1994) 179:873-879.
Selawry et al., "Extended Survival of MHC-Compatible Islet Grafts From Diabetes-Resistant Donors in Spontaneously Diabetic BB/W Rat," Diabetes (1987) 36:1061-1067.
Johnstone & Thorpe, "Immunochemistry in Practice", by Blackwell Scientific Publications, Oxford, (1987) pp. 30-47.
Lee et al., "Fas Ligand Expression on an Activated Cytotoxic T-cell Line", FASEB J. (1994) 8:A770.
Takahashi et al., "Generalized Lymphoproliferative Disease in Mice, Caused by a Point Mutation in the Fas Ligand", Cell (1994) 76:969-976.
Takahashi et al., "Human Fas ligand:gene structure, chromosomal location and species specificity", International Immunology (1994( 6:1567-1574.
Bellgrau Donald
Duke Richard C.
Campbell Bruce R.
University Technology Corporation
LandOfFree
Use of fas ligand to supress T-lymphocyte-mediated immune respon does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of fas ligand to supress T-lymphocyte-mediated immune respon, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of fas ligand to supress T-lymphocyte-mediated immune respon will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1456579